Research
Driving innovation in neonatal sepsis through collaborative, multicentre research and global data networks.
Our Research Priorities
Diagnostic Innovation
Developing and validating point-of-care biomarker panels, molecular diagnostics, and AI-assisted clinical decision tools for rapid and accurate sepsis identification.
View Publications →Epidemiology & Surveillance
Building the global evidence base through the NSS Sepsis Registry, multicentre observational studies, and population-level surveillance networks.
Sepsis Registry →Therapeutics & Trials
Coordinating clinical trials on antimicrobial duration, adjunctive therapies, immunomodulation, and novel treatment strategies for neonatal sepsis.
Funding Opportunities →Recent Publications
Selected recent publications from NSS-affiliated research.
Multicenter Validation of a Combined Biomarker Panel for Early-Onset Sepsis in Preterm Neonates
A prospective study across 12 NICUs demonstrating 94% sensitivity and 89% specificity for a combination of IL-6, presepsin, and CRP measured at 6 hours of life.
View Abstract →Antibiotic Duration for Culture-Negative Suspected Neonatal Sepsis: A Systematic Review and Meta-Analysis
Meta-analysis of 28 studies showing no difference in outcomes between 36-48h and 5-7 day courses, supporting shorter empiric therapy in culture-negative cases.
View Abstract →Global Patterns of Neonatal Sepsis Aetiology: First Report from the NSS International Sepsis Registry
Analysis of 15,000 episodes across 45 centres reveals marked geographic variation in causative organisms and resistance patterns, highlighting the need for region-specific empiric regimens.
View Abstract →The NSS Global Sepsis Registry
The world's largest prospective registry of neonatal sepsis cases, capturing standardised data on demographics, risk factors, microbiology, treatment, and outcomes from NICUs across 6 continents.
Global Sepsis Registry
Accepting new site applications
Open EnrolmentFunding Your Research
The NSS offers competitive research grants for projects aligned with our strategic priorities. The next application cycle opens in June 2026.